Drugs Made In America Acquisition II (DMII) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 0 184 sessions, December 3, 2025 to September 23, 2026
- Largest daily move
- +0.5% close of December 19, 2025
Company Description
Drugs Made In America Acquisition II (NASDAQ: DMII) is classified in the shell companies industry within the Financial Services sector and carries a market capitalization of $647.2M.
DMII has gained 2.6% so far this year. The last closing price was $10.16.
For FY2025, Drugs Made In America Acquisition II reported net income of $4.2M.
This page collects what Stock Titan holds for DMII, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In America Acquisition II (DMII) closed at $10.16 on September 23, 2026. So far this year, the price has gained 2.6%.
DMII Metrics & Rankings
Price returns through September 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
Drugs Made In America Acquisition II has filed 9 recent SEC filings, including 5 Form 8-K, 2 Form 10-Q, 1 Form 10-K, 1 Form NT 10-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMII SEC filings →
Financial Highlights
operating income reached -$488K, and net income was $4.2M. The company generated -$1.0M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In America Acquisition II (DMII) currently stands at 119.3 thousand shares, down 2.2% from the previous reporting period, representing 0.2% of the float. Since December 2025, short interest has increased by 166.7%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Drugs Made In America Acquisition II (DMII) currently stands at 1.9 days, down 98.8% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 86% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 159.6 days.
DMII Company Profile & Sector Positioning
Drugs Made In America Acquisition II (DMII) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the NASDAQ.